NCT06508216View on ClinicalTrials.gov

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 17, 2025

Study Completion Date

December 17, 2027

Conditions
Breast Cancer
Interventions
DRUG

Dato-DXd

Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days

DRUG

Durvalumab

Patients in module 2 only will receive Durvalumab 1120mg every 21 days

Trial Locations (1)

Unknown

RECRUITING

Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER